Zentalis Pharmaceuticals Stock
Zentalis Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Julia Marie Eastland
- Employees
- 106
- Market cap
- $152 M
- IPO
- 03/04/2020
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on…
Zentalis Pharmaceuticals stock: price history
1D
-4.9%
1W
-19.3%
1M
-31.3%
6M
-54.1%
YTD
+57.8%
1Y
+36.5%
2Y
-28.5%
5Y
-97.2%
10Y
–
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~7% stronger price swings than usual
Ask the agents about Zentalis Pharmaceuticals
Analyst assessment of Zentalis Pharmaceuticals
PRICE TARGET LOW
US$5.00
CONSENSUS
US$7.67
MEDIAN
US$8.00
PRICE TARGET HIGH
US$10.00
0
STRONG BUY
8
BUY
4
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 10/04/2026
Zentalis Pharmaceuticals stock metrics
P/E
-0.87
P/B
1.04
EV/EBITDA
-0.95
RETURN ON EQUITY
-54.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.26
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
68.2%
FLOAT SHARES
48,556,208
AVG. DAILY VOLUME (30D)
1,235,624
Insider transactions (SEC)
Bruns Ingmar
WALTERS GROUP
Johnson David Michael
Skvarka Jan
Myers Scott Dunseth
Institutional holders
Comparable stocks
Frequently asked questions about Zentalis Pharmaceuticals stock
What does Zentalis Pharmaceuticals do?
Zentalis Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Julia Marie Eastland, the company employs around 106 people.
The IPO was on 03/04/2020; the stock trades on NASDAQ under the ticker ZNTL.
What do analysts say about Zentalis Pharmaceuticals stock?
12 analysts rate the stock, the consensus is Buy (as of 10/04/2026).
The average price target is US$7.67, ranging from US$5.00 to US$10.00, with a median of US$8.00.
This is an external assessment, not a statement by Market Jury.
When does Zentalis Pharmaceuticals report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly 7% stronger than usual.
Does Zentalis Pharmaceuticals pay a dividend?
No, Zentalis Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Zentalis Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Zentalis Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Zentalis Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.